Other formats:
BibTeX
LaTeX
RIS
@article{1545971,
author = {Tibaut, Miha and Caprnda, Martin and Kubatka, Peter and Sinkovic, Andreja and Valentova, Vanda and Filipova, Slavomira and Gazdikova, Katarina and Gaspar, Ludovit and Mozos, Ioana and Egom, Emmanuel E. and Rodrigo, Luis and Kružliak, Peter and Petrovic, Daniel},
article_location = {NEW YORK},
article_number = {5},
doi = {http://dx.doi.org/10.1016/j.hlc.2018.06.1057},
keywords = {Biomarkers; Atherosderosis; High sensitivity C-reactive protein},
language = {eng},
issn = {1443-9506},
journal = {HEART LUNG AND CIRCULATION},
title = {Markers of Atherosclerosis. Part 1, Serological Markers},
url = {http://dx.doi.org/10.1016/j.hlc.2018.06.1057},
volume = {28},
year = {2019}
}
TY - JOUR
ID - 1545971
AU - Tibaut, Miha - Caprnda, Martin - Kubatka, Peter - Sinkovic, Andreja - Valentova, Vanda - Filipova, Slavomira - Gazdikova, Katarina - Gaspar, Ludovit - Mozos, Ioana - Egom, Emmanuel E. - Rodrigo, Luis - Kružliak, Peter - Petrovic, Daniel
PY - 2019
TI - Markers of Atherosclerosis. Part 1, Serological Markers
JF - HEART LUNG AND CIRCULATION
VL - 28
IS - 5
SP - 667-677
EP - 667-677
PB - ELSEVIER SCIENCE INC
SN - 14439506
KW - Biomarkers
KW - Atherosderosis
KW - High sensitivity C-reactive protein
UR - http://dx.doi.org/10.1016/j.hlc.2018.06.1057
L2 - http://dx.doi.org/10.1016/j.hlc.2018.06.1057
N2 - Atherosclerosis is a major contributor to morbidity and mortality worldwide. With therapeutic consequences in mind, several risk scores are being used to differentiate individuals with low, intermediate or high cardiovascular (CV) event risk. The most appropriate management of intermediate risk individuals is still not known, therefore, novel biomarkers are being sought to help re-stratify them as low or high risk. This narrative review is presented in two parts. Here, in Part 1, we summarise current knowledge on serum (serological) biomarkers of atherosclerosis. Among novel biomarkers, high sensitivity C-reactive protein (hsCRP) has emerged as the most promising in chronic situations, others need further clinical studies. However, it seems that a combination of serum biomarkers offers more to risk stratification than either biomarker alone. In Part 2, we address genetic and imaging markers of atherosclerosis, as well as other developments relevant to risk prediction.
ER -
TIBAUT, Miha, Martin CAPRNDA, Peter KUBATKA, Andreja SINKOVIC, Vanda VALENTOVA, Slavomira FILIPOVA, Katarina GAZDIKOVA, Ludovit GASPAR, Ioana MOZOS, Emmanuel E. EGOM, Luis RODRIGO, Peter KRUŽLIAK and Daniel PETROVIC. Markers of Atherosclerosis. Part 1, Serological Markers. \textit{HEART LUNG AND CIRCULATION}. NEW YORK: ELSEVIER SCIENCE INC, 2019, vol.~28, No~5, p.~667-677. ISSN~1443-9506. Available from: https://dx.doi.org/10.1016/j.hlc.2018.06.1057.
|
